Childhood cancer survivors have an increased risk of cardiovascular disease (CVD) and diabetes mellitus. Because diabetes is a potentially modifiable risk factor for CVD in the general population, it is important to understand how diabetes affects the risk of CVD among childhood cancer survivors. METHODS: This study examined the risk of CVD among survivors with diabetes and 142,742 population comparison subjects. From the national cancer registries of the 5 Nordic countries, 29,324 one-year survivors of cancer diagnosed before the age of 20 years between 1968 and 2008 were identified. Study subjects were linked to the national hospital registers. The cumulative incidence of CVD was determined with competing risk methods. A Cox proportional hazards model was used to estimate the effects of diabetes and cancer on the hazard of CVD. The interaction between diabetes and cancer was analyzed. RESULTS: Diabetes was diagnosed in 324 of the 29,324 one-year survivors, and CVD was diagnosed in 2108. The hazard of diabetes was 1.7 times higher among survivors than comparison subjects (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.5-1.9), whereas the HR of CVD was 3.6 (95% CI, 3.3-3.8) 1 to 15 years after the cancer diagnosis and 1.9 (95% CI, 1.8-2.0) after more than 15 years. Individuals with diabetes had a 2.4 times higher hazard of CVD (95% CI, 2.1-2.8) among both survivors and comparison subjects in comparison with individuals without diabetes. CONCLUSIONS: Childhood cancer survivors with diabetes have a markedly increased risk of CVD in comparison with survivors without diabetes. However, diabetes does not increase the risk of CVD more in survivors than the general population. Cancer 2018;124:4393-4400.
INTRODUCTION
The remarkable improvement in the treatment of childhood cancer during the past 5 decades has resulted in a rapidly growing population of long-term survivors. 1 However, these advances in treatment and survival come at a price, and many survivors face an increased risk for a broad range of treatment-induced sequelae, most of which become clinically apparent many years after the children have been cured. 2, 3 It is well established that childhood cancer survivors have an increased risk of cardiovascular morbidity and mortality, which is associated with exposure to anthracycline therapy and chest-directed radiotherapy. [4] [5] [6] [7] [8] Previous research has also shown that childhood cancer survivors have an increased risk for diabetes mellitus. [9] [10] [11] [12] [13] Diabetes mellitus is, in turn, a well-known risk factor for cardiovascular disease (CVD) in the general population. [14] [15] [16] Yet, within the survivor cohort of the Childhood Cancer Survivor Study (CCSS), diabetes was not found to potentiate cancer therapy-associated risk for CVD except for the risk of heart failure among those treated with chest-directed irradiation. 17 In the general population, several studies have shown that early diagnosis and improved treatment of diabetes decrease the risk of complications of diabetes, including CVD. 16, 18, 19 Therefore, it is important to fully understand how diabetes, a potentially modifiable risk factor, affects the risk of CVD among childhood cancer survivors and whether the impact of diabetes on the risk of CVD in survivors differs from that in the general population. Using the unique resources of Adult Life After Childhood Cancer in Scandinavia (ALiCCS), a large population-based cohort of Nordic childhood cancer survivors, we address these questions by examining the risk of CVD overall and the risk for
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MATERIALS AND METHODS

Survivor and Comparison Cohorts
This study is part of the Nordic collaborative study ALiCCS (https://www.cancer.dk/aliccs/). 20 The ALiCCS study was approved by the national bioethics committee, the data protection authority, or the national institute for health and welfare in the respective countries (Denmark, 2010-41-4334;
Finland, THL/520/5.05.00/2016; Iceland, VSN 10-041; Norway, 2011/884; and Sweden, Ö 10-2010, 2011/19) .
The basic childhood cancer cohort of ALiCCS includes 43,909 individuals registered with a cancer diagnosis before the age of 20 years in Denmark, Finland, Iceland, Norway, and Sweden between the start of the cancer registries in the 1940s and 1950s and December 31, 2008, and it has been described in detail elsewhere. 20 For each childhood cancer patient, 5 comparison subjects were randomly selected from the national population registers: they were alive on the date of the cancer diagnosis of the corresponding childhood cancer patient; were of the same sex, age, and country (Denmark and Iceland) or county/municipality (Finland, Norway and Sweden) of residence; and did not have a cancer diagnosis before the age of 20 years. For 317 survivors, fewer than 5 comparison subjects were available, and this left 219,131 individuals for the study. Information on vital status and migration during follow-up was collected from the national population registers for all study subjects.
Before the linkage of study subjects to the national hospital registers, we excluded those in whom more than 1 primary cancer had been diagnosed in childhood (305 patients), those who had died or emigrated before the start of the national hospital registers (Sweden, stepwise inclusion of counties in 1964 -1987 and nationwide since 1987 Finland, 1975; Denmark, 1977; Iceland, 1999; and Norway, 2008 ; 7251 patients and 5146 comparison subjects), and those who had died or had been censored during the first year after the date of the cancer diagnosis or within an equivalent time lag for the comparison subjects (3193 patients and 1093 comparison subjects). This resulted in a cohort of 33,160 one-year cancer survivors and 212,892 comparison subjects.
Hospital Contacts for Diabetes and CVD
The nationwide hospital registers contain information on virtually all nonpsychiatric hospital admissions in each of the 5 countries. 21, 22 Registration is mandatory and recorded by the treating physician. Each hospital admission initiates a record, which includes the personal identification of the patients, dates of admission and discharge, a primary discharge diagnosis, and supplementary diagnoses coded according to the International Classification of Diseases, Seventh Revision (ICD-7), ICD-8, ICD-9, and ICD-10. All first hospital admissions and hospital-based outpatient visits with a primary or supplementary discharge diagnosis of diabetes mellitus (ICD-10 codes E10 and E11) and CVD (Table 1) were identified for all study subjects. The subgroups of ischemic heart disease (ICD-10 codes I20-I25) and cerebrovascular disease (ICD-10 codes I60-I69 and G45) were identified within the CVD group. Diagnostic categories of ICD-7, ICD-8, and ICD-9 were adapted to ICD-10 to the extent possible. Study subject with a hospital contact for diabetes mellitus (60 survivors and 293 comparison subjects) or CVD (371 survivors and 424 comparison subjects) before the date of cancer diagnosis or the corresponding date for the equivalent comparison subjects were excluded. Because the focus of this study was the effect of diabetes on the risk of CVD, only diabetes events preceding CVD were included in the analyses. Furthermore, we excluded individuals in whom a congenital malformation of the circulatory system had been diagnosed (ICD-10 codes Q20-Q28; 281 survivors and 768 comparison subjects) and those with a congenital chromosomal abnormality (ICD-10 codes Q90-Q99; 197 survivors and 206 comparison subjects), who might have confounded any causal association between cancer treatment, diabetes, and CVD. This resulted in a cohort of 32,251 one-year survivors and 211,201 comparison subjects. However, because of the probable selection bias regarding survivors diagnosed with cancer in the earlier decades of the cancer registries and still alive at the start of follow-up in the hospital registers and because information on their possible hospital contacts before the hospital registers became operational was not available, only 1-year survivors diagnosed with cancer in 1968 and onward and their corresponding comparison subjects were included in the analyses. Thus, the final cohort included 29,324 one-year survivors and 142,742 comparison subjects. Of these 1-year survivors, 15,759 (54%) were under continuous follow-up within the hospital registries for 5 years or more after their cancer diagnosis.
Statistical Analysis
In this longitudinal analysis, follow-up for a first hospital contact for diabetes and CVD started 1 year after the Cancer November 15, 2018 date of the cancer diagnosis or the corresponding date for the comparison subjects or at the start of the hospital registers, whichever occurred last. Follow-up ended on the date of death, emigration, or the end of the study The cumulative incidence of CVD with corresponding 95% confidence intervals (CIs) was estimated with the competing risk of death taken into account with the Aalen-Johansen estimator. 23 The time since cancer diagnosis and the corresponding date of inclusion for comparison subjects were used as the underlying time scale. A stratified Cox proportional hazards model was used to estimate the effect of a preceding diagnosis of diabetes and childhood cancer on the cause-specific hazards of CVD, ischemic heart disease, and cerebrovascular disease. The model was stratified by the age at diagnosis/inclusion, the year of diagnosis/inclusion, and sex. The age at cancer diagnosis/inclusion and the year of diagnosis/inclusion were categorized into 4 groups: 0 to 4, 5 to 9, 10 to 14, and 15 to 19 years and 1968-1977, 1978-1987, 1988-1997, and 1998-2008 , respectively. Schoenfeld residuals were used to test the proportionality assumption of the fitted Cox proportional hazards models. 24 Because of violations of the proportionality assumption when survivors and comparison subjects were compared, we split the follow-up time of survivors at 15 years after the cancer diagnosis. Thus, we estimated the effects of being a 1-year childhood cancer survivor in comparison with a comparison subject on the hazard of CVD 1 to 15 years after the cancer diagnosis and from 15 years after the cancer diagnosis until the end of follow-up. We thereby ensured that the proportionality assumption was fulfilled. To investigate whether the effect of diabetes on the hazard of CVD was different among survivors and comparison subjects, an analysis including an interaction between diabetes and childhood cancer was conducted.
To estimate the effects of sex, cancer type, treatment era, and diabetes on the risk of CVD, ischemic heart disease, and cerebrovascular diseases, we conducted a multivariate analysis within the survivor cohort. A Cox proportional hazards model was used to estimate the effects of these variables on the cause-specific hazards of CVD, ischemic heart disease, and cerebrovascular diseases with the time since cancer diagnosis as the underlying time scale. The models were stratified by the age at cancer diagnosis (4 age groups as discussed previously). The following covariates were used: type of cancer (central nervous system [CNS] tumors, leukemia and lymphoma, and solid tumors), treatment era (4 time periods as discussed previously), and diabetes. In all analyses, the diagnosis of diabetes was included as a time-dependent covariate. Accordingly, we estimated the robust standard errors. Results are presented as hazard ratios (HRs) with corresponding 95% CIs. R statistical software (version Cancer November 15, 2018
3.4.1) and packages etm and survival were used for the statistical analyses.
RESULTS
In this cohort of 29,324 one-year survivors of childhood cancer, 324 and 2108 individuals were diagnosed with diabetes and CVD, respectively, during follow-up. The corresponding numbers among the 142,742 comparison subjects were 1160 and 5275, respectively. Furthermore, within the survivor cohort, 224 and 443 individuals were diagnosed with ischemic heart disease and cerebrovascular disease ( Table 2 ). Figure 1 shows the cumulative incidences of CVD among survivors and comparison subjects with and without diabetes. The cumulative incidence of CVD among survivors with diabetes increased more rapidly during the first 15 years after the cancer diagnosis, whereas the cumulative incidence among the comparison subjects with diabetes increased slowly the first 20 years after inclusion. However, there was an overlap of CIs.
The hazard of diabetes during follow-up was 1.7 times higher among survivors than comparison subjects (HR, 1.7; 95% CI, 1.5-1.9), whereas the hazard of CVD was increased 3.6 times (HR, 3.6; 95% CI, 3.3-3.8) 1 to 15 years after the cancer diagnosis and 1.9 times more than 15 years after the cancer diagnosis (HR, 1.9; 95% CI, 1.8-2.0). When we compared the cause-specific hazards of CVD among survivors and comparison subjects as well as the effect of diabetes, individuals with diabetes had a 2.4 times higher hazard of CVD (HR, 2.4; 95% CI, 2.1-2.8) than individuals without diabetes in both the survivor and comparison cohorts (Table 3 ). There was no statistically significant difference in the effect of diabetes on the hazard of CVD between survivors and comparison subjects (HR for the interaction of CVD and diabetes mellitus 1 to 15 years after the cancer diagnosis, 1.2; 95% CI, 0.6-2.4; P = .6; HR for the interaction of CVD and diabetes mellitus more than 15 years after the cancer diagnosis, 1.2; 95% CI, 0.8-1.8; P = .3). Thus, for survivors with diabetes, the HR of CVD was 8.7 (95% CI, 7.3-10.2) 1 to 15 years and 4.7 (95% CI, 4.0-5.5) more than 15 years after the cancer diagnosis in comparison with comparison subjects without diabetes. Table 4 shows the results from the within-cohort analysis investigating the effect of diabetes as well as the effects of sex, cancer type, and treatment era on the hazard of CVD, ischemic heart disease, and cerebrovascular disease.
Within-Cohort Analyses
Survivors with diabetes were found to have a 2.9-fold increased risk of CVD in comparison with survivors without diabetes (95% CI, 2.1-3.9). Furthermore, diabetes increased the risk of ischemic heart disease and cerebrovascular dis- There was no significant effect of sex on the risk of CVD or cerebrovascular disease, whereas female survivors had a significantly lower risk of ischemic heart disease in comparison with male survivors (HR, 0.5; 95% CI, 0.4-0.7). Compared with survivors diagnosed with cancer between 1968 and 1977, survivors treated in later decades had a higher risk of CVD, with an HR of 3.1 (95% CI, 2.6-3.8) for survivors diagnosed with cancer between 1998 and 2008. We found no significant effect of treatment era on the risk of ischemic heart disease or cerebrovascular disease apart from a slight increase in the risk of ischemic heart disease among those diagnosed with cancer in 1988-1997 versus 1968-1977 (HR, 1.9; 95% CI, 1.1-3.3). Included cardiovascular diseases are shown in Table 1 .
Cancer November 15, 2018 DISCUSSION This population-based study of 1-year survivors of childhood cancer shows that survivors with diabetes have a markedly increased risk of developing CVD in comparison with survivors without diabetes. This increase in risk is seen throughout the follow-up. However, diabetes does not increase the risk of CVD to a larger extent among survivors versus the general population. In this cohort, 1-year survivors had a 1.7 times increased risk of diabetes in comparison with the general population, and this is in accordance with earlier reports. 9, 11, 13 The increase in the risk of CVD in the current survivor cohort versus the general population is also in line with previously published results. 5, 6 Notably, we show that the increase in risk for CVD among survivors was higher the first 15 years after the cancer diagnosis, although it was still almost 2-fold after 15 or more years.
We have demonstrated that survivors with diabetes have an almost 2.5-fold increased risk of CVD in comparison with survivors without diabetes. Moreover, we have shown for the first time that diabetes is not a more significant risk factor for CVD among survivors than the general population. In a CCSS study investigating risk factors for major cardiac events, diabetes alone significantly increased the risk of heart failure and arrhythmia among survivors treated with chest-directed irradiation. 17 However, there was no increase in relative risk for coronary heart disease or valvular disease in survivors who had received chest-directed radiotherapy or for heart failure in patients treated with anthracyclines. Survivors treated with chest-directed irradiation did not have a statistically significant increase in relative risk due to the interaction between cardiotoxic exposure and the acquired risk factor diabetes for the studied CVDs, except for heart failure. The difference in the distribution of CVD, where those selected in the CCSS (coronary artery disease, heart failure, valvular disease, and arrhythmia) constituted only a portion of those included in our study, 6 could have contributed at least partly to the difference in results. Also, unlike the CCSS study, the analyses of CVD in the current study were not restricted to patients who received cardiotoxic therapy but included all survivors. Lastly, differences in study design, Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio. Included CVDs are shown in Table 1 .
Cancer November 15, 2018 where the CCSS included only children diagnosed with cancer up to 1986, was restricted to 5-year survivors, and was based on self-report, could have contributed to differences in results between the 2 studies. Although this study shows that diabetes does not affect the risk of CVD to a greater extent among survivors than comparison subjects, the risk of CVD among survivors is, nonetheless, elevated and, therefore, of substantial importance. Because it has been shown that early diagnosis and improved treatment of diabetes decrease the risk of later complications of diabetes, including CVDs, in the general population, 16, 18, 19 it is likely that early detection of diabetes through screening as well as intensified efforts for early and optimal treatment could reduce the risk of complications also among childhood cancer survivors with diabetes. This could, in turn, lead to a decline in morbidity and mortality in this vulnerable population. Therefore, screening for and treatment of diabetes as well as optimal counselling to avoid/postpone the onset of both diabetes and CVD are essential parts of the needed long-term follow-up care of childhood cancer survivors.
A multivariate regression analysis, adjusted for sex, age at cancer diagnosis, cancer type, and treatment era, has revealed that survivors with diabetes have an almost 3 times higher risk of CVD than survivors without diabetes. Importantly, diabetes in childhood cancer survivors increases the risk of ischemic heart disease more than 3 times and the risk of cerebrovascular disease more than 4 times. In the CCSS, diabetes alone did not lead to a significantly higher risk for coronary heart disease among survivors treated with chest-directed irradiation. 17 Again, the differences in inclusions in the 2 aforementioned studies may have contributed to the discrepancies in results. In addition, the current study does not include information on the prevalence of cardiovascular risk factors other than diabetes. In the general population, diabetes is a well-known risk factor for cerebrovascular disease in addition to heart disease. 25, 26 Among childhood cancer survivors, an increased risk for cerebrovascular disease has been found, especially among CNS tumor survivors, predominantly because of irradiation treatment. [27] [28] [29] In the CCSS, diabetes was not identified as a risk factor for stroke in the full childhood cancer survivor cohort, but diabetes in combination with hypertension had a strong effect on stroke risk in CNS tumor survivors. 30 When one is interpreting the results of this study, it is important to keep in mind that we used hospital-based inpatient and outpatient diagnoses of diabetes and CVD. Although this approach increases the validity of the diagnostic information, patients with diabetes and CVD exclusively diagnosed by a general practitioner are not included. However, this limitation also applies to the comparison cohort. Yet, our results might have been influenced by better medical surveillance of survivors, and this might have led to potential overestimations of their risk of diabetes and CVD. Underascertainment of advanced disease seems unlikely. The lack of cancer treatment data hindered investigations of treatment-related risk factors for diabetes and CVD. Furthermore, separate analyses of type 1 diabetes and type 2 diabetes were hindered by low numbers. Within ALiCCS, case-cohort studies of selected outcomes, including diabetes, are ongoing. Abbreviations: CI, confidence interval; CNS, central nervous system; HR, hazard ratio. Included cardiovascular diseases are shown in Table 1 .
a The analysis was stratified by the age at cancer diagnosis.
Cancer November 15, 2018 In conclusion, childhood cancer survivors are at increased risk for both diabetes and CVD. This study also demonstrates that diabetes substantially increases the risk of CVD, ischemic heart disease, and cerebrovascular disease in childhood cancer survivors. Although we have shown that diabetes does not increase the risk of CVD to a larger extent in survivors than the general population, the substantial increase in the risk of CVD among survivors with diabetes calls for tailored counselling and follow-up care, including the early diagnosis and accurate treatment of diabetes, with the aim of decreasing or preventing the negative impact of diabetes on the development of cardiovascular morbidity and mortality in long-term survivors of childhood cancer.
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